Last reviewed · How we verify
FB825 in intravenous route — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
FB825 in intravenous route (FB825 in intravenous route) — Oneness Biotech Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| FB825 in intravenous route TARGET | FB825 in intravenous route | Oneness Biotech Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- FB825 in intravenous route CI watch — RSS
- FB825 in intravenous route CI watch — Atom
- FB825 in intravenous route CI watch — JSON
- FB825 in intravenous route alone — RSS
Cite this brief
Drug Landscape (2026). FB825 in intravenous route — Competitive Intelligence Brief. https://druglandscape.com/ci/fb825-in-intravenous-route. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab